What one share of Tscan Therapeutics holds
We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT).
Tscan Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.05 |
|---|---|
| Profit | −$0.91 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$0.91 |
| Cash and investments | $0.77 |
| Debt | $0.25 |
| Book value | $0.53 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$28.52 | $4.63 | −$7.93 | — | −$37.38 |
| 2021 | $0.87 | −$4.17 | $0.85 | −$5.03 | — | — |
| 2022 | $0.56 | −$2.75 | $0.18 | −$2.94 | — | $4.13 |
| 2023 | $0.32 | −$1.36 | $0.05 | −$0.98 | — | $2.30 |
| 2024 | $0.03 | −$1.14 | $0.03 | −$1.02 | — | $2.15 |
| 2025 | $0.08 | −$1.00 | $0.03 | −$1.08 | — | $0.95 |
Common questions about Tscan Therapeutics
How much does one share of Tscan Therapeutics earn?
Over the last 12 months, Tscan Therapeutics lost $0.91 for each share on $0.05 of sales.
Does Tscan Therapeutics pay a dividend?
Tscan Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Tscan Therapeutics’s book value per share?
Tscan Therapeutics’s book value is $0.53 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Tscan Therapeutics have?
Each share of Tscan Therapeutics has $0.77 of cash and investments and $0.25 of debt, as of June 30, 2026.
What is Tscan Therapeutics’s free cash flow per share?
−$0.91 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Tscan Therapeutics bought back shares?
Tscan Therapeutics’s share count rose about 14068% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.